Literature DB >> 8562481

Mitogenic signaling by transfected neuromedin B receptors in Rat-1 cells.

E B Lach1, S Broad, E Rozengurt.   

Abstract

The rat neuromedin B (NMB) receptor was expressed in Rat-1 fibroblasts to elucidate the signaling pathways and mitogenic effects mediated by this seven-transmembrane domain receptor. Receptor expression was verified by ligand binding and Ca2+ mobilization, which were blocked by the NMB receptor antagonist D-Nal-Cys-Tyr-D-Trp-Orn-Val-Cys-Nal-NH2. NMB acted as a potent growth factor promoting DNA synthesis and cell proliferation in serum-free medium in Rat-1 cells transfected with the NMB receptor. Prior to DNA synthesis, NMB stimulated phosphorylation of 80K/MARCKS, a major substrate of protein kinase C, which could be prevented by the selective protein kinase C inhibitor GF 109203X. Furthermore, NMB induced a rapid p42MAPK activation and tyrosine phosphorylation of multiple proteins including p125FAK and paxillin. The half-maximal concentrations (EC50) of NMB required to induce DNA synthesis (0.7-0.9 nM) and cell proliferation (0.7-1 nM) paralleled the Kd for 125I-[D-Tyr0]NMB binding and the EC50 values for the induction of the early signaling events. Thus, NMB can activate multiple signal transduction pathways and act as a sole mitogen through its receptor expressed in Rat-1 fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562481

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  7 in total

1.  Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.

Authors:  Terry W Moody; Marc J Berna; Samuel Mantey; Veronica Sancho; Lisa Ridnour; David A Wink; Daniel Chan; Giuseppe Giaccone; Robert T Jensen
Journal:  Eur J Pharmacol       Date:  2010-04-11       Impact factor: 4.432

2.  Cholecystokinin-stimulated tyrosine phosphorylation of p125FAK and paxillin is mediated by phospholipase C-dependent and -independent mechanisms and requires the integrity of the actin cytoskeleton and participation of p21rho.

Authors:  L J García; J A Rosado; A González; R T Jensen
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

3.  The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors.

Authors:  Christopher L Herold; David J Behm; Peter T Buckley; James J Foley; William E Wixted; Henry M Sarau; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

4.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

Review 5.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

6.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

7.  Hypoxia regulates the expression of the neuromedin B receptor through a mechanism dependent on hypoxia-inducible factor-1α.

Authors:  Hyun-Joo Park; Mi-Kyoung Kim; Su-Ryun Kim; Soo-Kyung Bae; Moon-Kyoung Bae
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.